Skip to main content

Table 2 Results of the association between SNHG15 and clinicopathological outcomes

From: Long non-coding RNA SNHG15 in various cancers: a meta and bioinformatic analysis

       Heterogeneity
outcome studies(n) OR 95%CI P value Model Chi2 I2 P Value
age(< 60 vs ≥60) 4 0.98 0.65–1.48 0.912 Fixed 1.84 0% 0.607
gender (male vs female) 9 0.95 0.73–1.25 0.728 Fixed 12.44 35.7% 0.133
TNM stage (III-IV vs I-II) 6 3.01 2.15–4.23 0.000 Fixed 2.76 0% 0.737
lymph node metastasis
(positive vs negative)
8 3.20 2.30–4.45 0.000 Fixed 3.20 0% 0.866
tumor size (large vs small) 7 1.88 0.91–3.89 0.087 Random 27.76 78.4% 0.000
overall survival 11 1.95 1.53–2.49 0.000 Fixed 6.43 0% 0.778
disease-free survival 2 2.31 1.48–3.61 0.000 Fixed 0.05 0% 0.822